Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Fenebrutinib First Drug in a Decade to Slow PPMS Disability
Genentech, part of the Roche Group, has released new late-breaking results from the Phase III FENtrepid study showing that its investigational Bruton’s tyrosine kinase inhibitor fenebrutinib met the primary endpoint of non-inferiority compared with Ocrevus in reducing disability progression in patients with primary progressive multiple sclerosis. Fenebrutinib reduced the risk of 12-week composite confirmed disability progression by 12 percent compared with Ocrevus with benefits visible as early as 24 weeks. The study measured disability using a composite endpoint that includes the Expanded Disability Status Scale for overall functional ability, the timed 25-foot walk for mobility, and the nine-hole peg test for upper limb function, with the strongest effect observed in upper limb performance, reducing risk by 26 percent.
Median Technologies Gets FDA Clearance for AI Lung Cancer Device
Median Technologies, a global leader in AI-powered medical imaging and early cancer detection solutions, announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its eyonis LCS software. This innovative tool, powered by artificial intelligence and machine learning, is the first computer-aided detection and diagnosis system specifically designed to support lung cancer screening programs. Lung cancer remains the leading cause of cancer deaths in the United States, and outcomes are significantly improved when the disease is identified at an early stage. Low-Dose CT screening can detect stage one lung cancer when curative treatment is possible, resulting in approximately 80 percent long-term survival compared with roughly 15 percent five-year survival for cases identified after symptoms appear.
R1 Appoints Andy Brailo as Chief Commercial Officer
R1, a leader in healthcare revenue management, has announced that Andy Brailo has joined the company as Chief Commercial Officer. In this role, Mr. Brailo will lead R1’s commercial strategy, oversee growth initiatives, expand the customer base, and strengthen go-to-market execution to meet the rising demand for R1’s AI-enabled revenue cycle solutions. Mr. Brailo brings more than 25 years of experience in healthcare sales, operations, process management, and customer service. He previously served as Chief Commercial Officer at Premier Inc., where he worked closely with members, suppliers, and internal teams to design scalable solutions that helped healthcare providers improve quality while managing costs.
TG Therapeutics Partners with Christina Applegate to Raise MS Awareness
TG Therapeutics, Inc., a leading biopharmaceutical company, has announced a collaboration with actress Christina Applegate to raise awareness of multiple sclerosis and foster meaningful discussions for those living with the condition. Christina Applegate, who has been managing MS for five years, will spearhead a national initiative designed to amplify the experiences of people living with MS, highlight the daily realities of the disease, and encourage conversations about what comes next on each individual’s terms. The platform will feature Christina’s personal reflections on living with MS, navigating the healthcare system, making long-term decisions, and maintaining quality of life while managing a chronic illness. It will also include expert insights from leading MS specialists to help people living with MS and their caregivers make informed decisions.
PDS Health Highlights Connection Between Oral and Heart Health
During American Heart Month in February, PDS Health, a leading integrated healthcare support organization, is highlighting the important connection between oral health and cardiovascular wellness. Regular dental visits play a key role in preventing heart disease, the leading cause of death in the United States. Research indicates that periodontal disease, commonly known as gum disease, is linked to a higher risk of heart attack, stroke, atrial fibrillation, heart failure, peripheral artery disease, chronic kidney disease, and cardiac death, according to the American Heart Association. In December 2025, the AHA released a scientific statement confirming a link between gum disease and atherosclerotic cardiovascular conditions such as angina and stroke caused by plaque buildup in the arteries. Because periodontal disease is a prevalent but often undiagnosed chronic condition in adults, early detection during routine dental visits is essential for protecting both oral and overall health.
To share your insights, please write to us at sudipto@intentamplify.com
